Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 18/20 | 0.73 |
| ▸ | CDK2 | P24941 | 16/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 9/20 | 0.73 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14368151 | 0.89 | AURKA (0.69) | AURKACDK2MAPK1MAP3K7FLT3 | |
| SCHEMBL12020890 | 0.89 | AURKA (0.78) | AURKACDK2MAPK1MAP3K7FLT3 | |
| SCHEMBL14252641 | 0.88 | AURKA (0.77) | AURKACDK2MAPK1MAP3K7FLT3 | |
| SCHEMBL14368149 | 0.87 | AURKA (0.75) | AURKACDK2MAPK1MAP3K7FLT3 | |
| SCHEMBL14368142 | 0.87 | AURKA (0.84) | AURKACDK2MAPK1MAP3K7FLT3 | |
| SCHEMBL12020865 | 0.87 | AURKA (0.75) | AURKACDK2MAPK1MAP3K7FLT3 | |
| SCHEMBL14252620 | 0.87 | AURKA (0.75) | AURKACDK2MAPK1MAP3K7FLT3 | |
| SCHEMBL14368140 | 0.85 | AURKA (0.79) | AURKACDK2MAPK1MAP3K7FLT3 | |
| SCHEMBL12020889 | 0.85 | AURKA (0.73) | AURKACDK2MAPK1MAP3K7FLT3 | |
| SCHEMBL14368152 | 0.84 | AURKA (0.80) | AURKACDK2MAPK1MAP3K7FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501415-B2 | Selective inhibitors of ERK protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-10 | — | — | US | disclosed |
| US-20060160807-A1 | Selective inhibitors of ERK protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160807-A1 | Selective inhibitors of ERK protein kinase and uses thereof | MAP3K20, MAP4K2, MAP4K1 | AURKA 832/4885CDK2 87/4885MAPK1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.